[go: up one dir, main page]

WO2009082459A3 - Anti-aging composition containing resveratrol and method of administration - Google Patents

Anti-aging composition containing resveratrol and method of administration Download PDF

Info

Publication number
WO2009082459A3
WO2009082459A3 PCT/US2008/013828 US2008013828W WO2009082459A3 WO 2009082459 A3 WO2009082459 A3 WO 2009082459A3 US 2008013828 W US2008013828 W US 2008013828W WO 2009082459 A3 WO2009082459 A3 WO 2009082459A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
resveratrol
aging
slow release
aging composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/013828
Other languages
French (fr)
Other versions
WO2009082459A2 (en
Inventor
Michael Todd Yatcilla
Dallas Clouatre
Edward Anthony Byrd
Fitzpatrick Amy Addington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natrol Inc
Original Assignee
Natrol Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natrol Inc filed Critical Natrol Inc
Publication of WO2009082459A2 publication Critical patent/WO2009082459A2/en
Publication of WO2009082459A3 publication Critical patent/WO2009082459A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Formulations and methods of treatment and putative prevention for aging (anti- aging composition) and for diseases or conditions of all reactive oxygen species-dependant illnesses, such as Alzheimer's disease, Parkinson's disease, diabetes mellitus, cardiovascular disease, cancer, hepatitis, and disorders associated with estrogen deficiencies including osteoporosis and breast cancer and for improving athletic performance of humans include resveratrol and two (2) or more of the following features or additional active ingredients: (1) slow release formulation of resveratrol; (2) pterostilbene; (3) quercetin; (4) fisetin, and (5) naringenin. Slow release is defined for the purposes of the present invention as releasing 95% of the active agent or agents in eight (8) hours through normal human gastrointestinal absorption.
PCT/US2008/013828 2007-12-24 2008-12-18 Anti-aging composition containing resveratrol and method of administration Ceased WO2009082459A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US910707P 2007-12-24 2007-12-24
US61/009,107 2007-12-24

Publications (2)

Publication Number Publication Date
WO2009082459A2 WO2009082459A2 (en) 2009-07-02
WO2009082459A3 true WO2009082459A3 (en) 2009-09-17

Family

ID=40351870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/013828 Ceased WO2009082459A2 (en) 2007-12-24 2008-12-18 Anti-aging composition containing resveratrol and method of administration

Country Status (2)

Country Link
US (1) US20090163580A1 (en)
WO (1) WO2009082459A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010150271A1 (en) * 2009-06-22 2010-12-29 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
CA2677950A1 (en) * 2009-09-17 2010-01-22 Gaspari Nutrition, Inc. Stilbene-based compositions and methods of use therefor
US20100119499A1 (en) * 2009-09-17 2010-05-13 Kneller Bruce W Stilbene-based compositions and methods of use therefor
US20110136751A1 (en) * 2009-10-06 2011-06-09 Green Molecular Use of Polyphenols in the Treatment of Cancer
EP2322159A1 (en) * 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
RU2437161C1 (en) * 2010-04-12 2011-12-20 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Method for reservatrol-based osteoporosis correction and fragility fracture prevention
RU2437160C1 (en) * 2010-04-12 2011-12-20 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Method for reservatrol and enalapril based osteoporosis correction and fragility fracture prevention
US11090313B2 (en) * 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
EP2422777A1 (en) * 2010-08-20 2012-02-29 Universitätsklinikum Freiburg Synergistic effect of modulators for NO metabolism and NADPH oxidase during sensitization of tumour cells
US9125824B1 (en) * 2010-10-06 2015-09-08 Innovitamin Organics, Llc Methods and systems for processing organic trans-resveratrol as dietary supplements
WO2012054936A1 (en) * 2010-10-22 2012-04-26 Barber Elizabeth K Treatment of neurodegenerative disease
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
EP2717876B1 (en) * 2011-06-06 2018-12-19 University of Iowa Research Foundation Substances and compostions for use in methods of inhibiting muscle atrophy
US20130296440A1 (en) * 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
CN102816090A (en) * 2012-09-10 2012-12-12 四川大学 Carbamate compounds, preparation method and application thereof
FR3005419B1 (en) 2013-05-13 2015-09-04 Agronomique Inst Nat Rech USE OF A COMBINATION OF TWO COMPOUNDS FOR THE TREATMENT AND / OR PREVENTION OF BONE DISORDERS
US9138453B2 (en) 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
WO2015077656A1 (en) * 2013-11-22 2015-05-28 Shoenwetter Phillip E Novel antioxidant formulations
CN106458871B (en) * 2014-05-12 2018-12-28 陶氏环球技术有限责任公司 Nitron compounds and their use in personal care
JP6126064B2 (en) * 2014-11-11 2017-05-10 ポーラ化成工業株式会社 Film-coated tablet containing a compound having a stilbene skeleton
WO2016081035A1 (en) * 2014-11-21 2016-05-26 Schoenwetter Phillip E Novel antioxidant formulations
CN109982706A (en) * 2016-08-22 2019-07-05 益力舒健康公司 Compositions and methods of nicotinamide riboside and pterostilbene for treating neurodegenerative disorders
US20190030044A1 (en) * 2017-07-26 2019-01-31 Richard Postrel Human life extension therapy through molecular, cellular and subcellular management of biochemical requirements of mitochondria and of other organelle processes associated with the advent of disease and/or aging
WO2019109044A1 (en) * 2017-12-01 2019-06-06 The Scripps Research Institute Methods and materials for assessing biological age and slowing the progress of excessive biological aging
IT201800000890A1 (en) * 2018-01-15 2019-07-15 Sirt500 Sagl NUTRACEUTICAL COMPOSITION FOR THE ACTIVATION OF SYRTUINS WITH ANTI-AGING / REVERSE-AGING EFFECT
KR20230116087A (en) * 2018-04-13 2023-08-03 유승현 Identification of granins as the pathogenic factor of alzheimer's disease and compositions and methods for inhibiting granin aggregation and treating alzheimer's disease
EP4291239A4 (en) * 2021-02-10 2025-04-09 Gero Pte. Ltd. COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS
WO2023076804A1 (en) * 2021-10-27 2023-05-04 Elysium Health Inc. Methods for treatment of menopausal syndromes
JP2025536415A (en) * 2022-11-07 2025-11-05 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Thymol or carvacrol for use in reducing biological age or its rate of increase
WO2025189074A1 (en) * 2024-03-08 2025-09-12 Anju Majeed Compositions for the management of sleep disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065667A2 (en) * 2003-12-29 2005-07-21 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
WO2005099761A1 (en) * 2004-04-07 2005-10-27 Resveratrol Partners, Llc Dietary supplement and method of processing same
US20060084135A1 (en) * 2003-07-01 2006-04-20 Howitz Konrad T Compositions for manipulating the lifespan and stress response of cells and organisms
EP1782802A1 (en) * 2004-07-20 2007-05-09 Universidad de Valencia Combined use of pterostilbene and quercetin for the production of cancer treatment medicaments
CN101015350A (en) * 2007-01-12 2007-08-15 南京大渊美容保健有限公司 Senescence delaying health care composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084135A1 (en) * 2003-07-01 2006-04-20 Howitz Konrad T Compositions for manipulating the lifespan and stress response of cells and organisms
WO2005065667A2 (en) * 2003-12-29 2005-07-21 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
WO2005099761A1 (en) * 2004-04-07 2005-10-27 Resveratrol Partners, Llc Dietary supplement and method of processing same
EP1782802A1 (en) * 2004-07-20 2007-05-09 Universidad de Valencia Combined use of pterostilbene and quercetin for the production of cancer treatment medicaments
CN101015350A (en) * 2007-01-12 2007-08-15 南京大渊美容保健有限公司 Senescence delaying health care composition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CALABRESE G: "NONALCOHOLIC COMPOUNDS OF WINE: THE PHYTOESTROGEN RESVERATROL AND MODERATE RED WINE CONSUMPTION DURING MENOPAUSE", DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, BIOSCIENCE EDIPRINT INC, XX, vol. XXV, no. 2/03, 26 November 1999 (1999-11-26), pages 111 - 114, XP001021116, ISSN: 0378-6501 *
CANDELARIO-JALIL EDUARDO ET AL: "Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia", 10 October 2007, JOURNAL OF NEUROINFLAMMATION, BIOMED CENTRAL LTD., LONDON, GB, PAGE(S) 25, ISSN: 1742-2094, XP021037912 *
KOPP P.: "Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the "French paradox"", EUROPEAN JOURNAL OF ENDOCRINOLOGY/ EUROPEAN FEDERATION OF ENDOCRINE SOCIETIES, vol. 138, no. 6, June 1998 (1998-06-01), U.K., pages 619 - 620, XP002524793 *
LU KWOK TUNG ET AL.: "Neuroprotective Effects of Resveratrol on Cerebral Ischemia-Induced Neuron Loss Mediated by Free Radical Scavenging and Cerebral Blood Flow Elevation", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 54, no. 8, 19 April 2006 (2006-04-19), USA, pages 3126 - 3131, XP002524792 *

Also Published As

Publication number Publication date
WO2009082459A2 (en) 2009-07-02
US20090163580A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
WO2009082459A3 (en) Anti-aging composition containing resveratrol and method of administration
AU2020201457B2 (en) Compositions and methods for managing or improving bone disorders, cartilage disorders, or both
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
CY1109929T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING FENOFIBRIAT AND METHOD FOR PREPARING IT
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
UA102429C2 (en) Pharmaceutical composition comprising an sglt2 inhibitor, a dppiv inhibitor and a third antidiabetic agent and use thereof
BRPI0500704A (en) rehydratable personal care compositions
WO2007127273A3 (en) Methods and compositions for altering cell function
MY143795A (en) Tetrahydropyridoindole derivatives
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
BRPI0417833A (en) benzofuran derivatives which may be used for the prophylaxis or treatment of 5-ht6 receptor-related disorders
WO2007016679A3 (en) Combination immediate release controlled release levodopa and carbidopa dosage forms
ATE418540T1 (en) GALLOYL PEPTIDES
BR112013009043B8 (en) compound, pharmaceutical composition, and use of a compound
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
WO2011022633A3 (en) Method of threating cancer
WO2005123651A8 (en) L-2-(α-HYDROXYPENTYL)BENZOATES, THE PREPARATION AND THE USE THEREOF
WO2005102309A3 (en) In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
WO2011028799A3 (en) Ganglioside transmucosal formulations
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
WO2007031326A3 (en) 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation
BR0210975A (en) Oral composition for use as a prophylactic, therapeutic and / or cosmetic agent for obesity / overweight in non-diabetic mammals, including humans and preparation of an oral composition.
WO2006071603A3 (en) Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure
JP2005035999A (en) Monoamine reuptake inhibitor with dicoppi

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08865803

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08865803

Country of ref document: EP

Kind code of ref document: A2